chat
CDC ACIP Meeting: COVID-19, Influenza, RSV + Pneumococcal Vaccines | Oct. 23
*The opinions expressed by the hosts and guests in this show are not necessarily the views of Children’s Health Defense.
Resources
Pneumococcal Vaccines | Presentation Slides
Economic Analysis and Public Health Impact of PCV | Presentation Slides
Summary of three economic analyses on the use of PCV | Presentation Slides
Summary of Work Group Interpretation of EtR and Policy Options | Presentation Slides
Influenza Work Group—Introduction | Presentation Slides
2023–24 End of Season Influenza Vaccine Effectiveness – United States | Presentation Slides
Highly Pathogenic Avian Influenza A (H5N1) | Presentation Slides
CHIKUNGUNYA VACCINES | Presentation Slides
Update on chikungunya and chikungunya vaccines | Presentation Slides
CHIKV VLP vaccine Bavarian Nordic’s chikungunya vaccine candidate | Presentation Slides
Work Group interpretation of data for virus-like particle chikungunya vaccine | Presentation Slides
ACIP COVID-19 Vaccines Work Group | Presentation Slides
Implementation Considerations for Additional COVID-19 Vaccine Doses | Presentation Slides
Effectiveness of COVID-19 vaccines | Presentation Slides
Economic analysis of an additional dose of the 2024-2025 COVID-19 vaccine | Presentation Slides
Maternal/Pediatric Respiratory Syncytial Virus (RSV) Work Group | Presentation Slides
Clesrovimab (MK-1654): Pediatric Clinical Program | Presentation Slides
Maternal & Pediatric RSV Work Group Interpretations and Next Steps | Presentation Slides


